Philadelphia Chromosome and B-cell Acute Lymphoblastic Leukemia in Elderly Patients
Author Information
Author(s): Muacevic Alexander, Adler John R, Saburi Masuho, Nishikawa Takumi, Maehara Kuniaki, Uraisami Keiichi, Takata Hiroyuki, Miyazaki Yasuhiko, Narahara Kumiko, Sasaki Hitohiro, Abe Miyuki, Kohno Kazuhiro, Nakayama Toshiyuki, Ohtsuka Eiichi
Primary Institution: Department of Hematology, Oita Prefectural Hospital, Oita, JPN
Hypothesis
The study aims to evaluate treatment outcomes of B-cell acute lymphoblastic leukemia/lymphoblastic lymphoma in elderly patients ineligible for transplantation.
Conclusion
Elderly patients with Philadelphia chromosome-positive ALL showed significantly longer overall survival and event-free survival than those with Philadelphia chromosome-negative ALL.
Supporting Evidence
- 93.1% of patients achieved complete response.
- Overall survival was significantly longer in Ph-positive patients.
- Median overall survival was 4.67 years.
Takeaway
Older patients with a specific genetic marker (Philadelphia chromosome) have better chances of surviving leukemia with new treatments.
Methodology
Retrospective study evaluating treatment outcomes in transplant-ineligible patients aged 65 years or older with newly diagnosed B-ALL/LBL.
Limitations
The study is limited by its retrospective nature, small sample size, and lack of MRD measurement in Ph-negative ALL patients.
Participant Demographics
Median age was 72 years, with 10 male and 19 female patients.
Statistical Information
P-Value
p=0.011 for OS; p=0.041 for EFS
Confidence Interval
OS: 95% CI 0.71-8.72; EFS: 95% CI 0.50-3.39
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website